The ECH1 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population targeting the ECH1 gene in the human colorectal adenocarcinoma HT29 cell line. This polyclonal population provides a heterogeneous loss-of-function model, enabling researchers to investigate the functional consequences of ECH1 disruption in peroxisomal fatty acid beta-oxidation and associated metabolic networks. By ablating ECH1 expression, these cells facilitate the study of lipid metabolism reprogramming and its impact on colorectal cancer cell biology.
HT29 cells are established from a human colorectal adenocarcinoma and serve as a widely used model for intestinal epithelial barrier function, colorectal cancer progression, and metabolic studies. Their epithelial origin and retention of key characteristics make them particularly suitable for investigating peroxisomal biology within the context of intestinal epithelium. The host cell line??s well-characterized signaling and metabolic pathways offer a reproducible platform for dissecting gene function in colorectal cancer research.
ECH1 encodes a peroxisomal enzyme that catalyzes the second step in peroxisomal fatty acid beta-oxidation, converting trans-2,3-enoyl-CoA to 3-hydroxyacyl-CoA. This reaction is integral to the generation of acetyl-CoA and NADH, linking lipid catabolism to cellular energy homeostasis. ECH1 is transcriptionally regulated by PPAR?? and PGC-1??, key regulators of peroxisomal biogenesis and fatty acid oxidation, and is also responsive to insulin signaling. Within the peroxisomal matrix, ECH1 interacts with the peroxisomal targeting signal receptor PEX5 and cooperates with HSD17B4 to sequentially process fatty acyl-CoA substrates. Disruption of ECH1 therefore perturbs the entire peroxisomal beta-oxidation spiral, potentially altering downstream metabolite pools and PPAR signaling.
In the HT29 colorectal adenocarcinoma background, ECH1 knockout provides a physiologically relevant system to explore how peroxisomal dysfunction influences malignant transformation, proliferation, and metabolic flexibility. Given the emerging role of lipid metabolism in colorectal cancer, this model enables dissection of peroxisome-specific contributions to tumor cell energetics, redox balance, and signaling. The disruption of ECH1 may compromise peroxisomal oxidation of very long-chain and branched-chain fatty acids, revealing compensatory mechanisms or vulnerabilities that could be exploited therapeutically.
This polyclonal knockout cell population is designed for a range of experimental applications, including the study of peroxisomal fatty acid oxidation in colorectal cancer, lipid metabolism reprogramming, and peroxisomal function in intestinal epithelium. Researchers can employ functional assays such as fatty acid oxidation assays, Seahorse metabolic flux analysis, and lipidomics to characterize metabolic shifts. Molecular analyses using RT-qPCR and western blotting can assess alterations in associated pathways, while proliferation and colonosphere formation assays evaluate phenotypic outcomes. Drug metabolism studies may further clarify how ECH1 loss influences therapeutic responses. For additional technical details, please contact Ascent Research.
